317 results on '"Sacco, Rodolfo"'
Number of results to display per page
Search Results
2. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
- Author
-
Scaravaglio, Miki, Nofit, Eugenia, Gallo, Paolo, Galati, Giovanni, Pezzato, Francesco, Rollo, Paolo, D’Ovidio, Erica, Coco, Barbara, Tortora, Annalisa, Fiorini, Cecilia, Venere, Rosanna, Scifo, Gaetano, Cannavò, Mariarita, Feletti, Valentina, Pizzolante, Fabrizio, Giannini, Edoardo Giovanni, Cotugno, Rosa, Fanella, Silvia, Losito, Francesco, Grassi, Giuseppe, Manfredi, Giulia Francesca, Buzzanca, Valerio, Omazzi, Barbara, Casella, Silvia, Zani, Francesca, Ricci, Chiara, Bellia, Valentina, Abenavoli, Ludovico, Morelli, Olivia, Crocè, Lory Saveria, Scivetti, Paolo, Panero, Antonio, Boano, Valentina, Poggi, Guido, Gimignani, Giancarlo, Conforti, Alessandro, Frazzetto, Evelise, Rapisarda, Laura, Demma, Shrin, De Vincentis, Antonio, Ampuero, Javier, Terracciani, Francesca, D’Amato, Daphne, Gerussi, Alessio, Cristoferi, Laura, Cazzagon, Nora, Bonaiuto, Emanuela, Floreani, Annarosa, Calvaruso, Vincenza, Cadamuro, Luca, Degasperi, Elisabetta, Morgando, Anna, Vanni, Ester, Lleo, Ana, Colapietro, Francesca, Alvaro, Domenico, Castellaneta, Antonino, Labanca, Sara, Viganò, Mauro, Distefano, Marco, Pace Palitti, Valeria, De Matthaeis, Nicoletta, Marzioni, Marco, Gómez-Dominguez, Elena, Montero, Jose-Luis, Molina, Esther, Garcia-Buey, Luisa, Casado, Marta, Berenguer, Marina, Conde, Isabel, Simon, Miguel-Angel, Fuentes, Javier, Costa-Moreira, Pedro, Macedo, Guilherme, Jorquera, Francisco, Morillas, Rosa-Maria, Presa, Jose, Sousa, Jose-Manuel, Gomes, Dario, Santos, Luis, Olveira, Antonio, Hernandez-Guerra, Manuel, Aburruza, Leire, Santos, Arsenio, Carvalho, Armando, Uriz, Juan, Gutierrez, Maria-Luisa, Perez, Elia, Chessa, Luchino, Pellicelli, Adriano, Marignani, Massimo, Muratori, Luigi, Niro, Grazia Anna, Brunetto, Maurizia, Ponziani, Francesca Romana, Pompili, Maurizio, Marra, Fabio, Galli, Andrea, Mussetto, Alessandro, Alagna, Giuliano, Simone, Loredana, Bertino, Gaetano, Rosina, Floriano, Cozzolongo, Raffaele, Russello, Maurizio, Baiocchi, Leonardo, Saitta, Carlo, Terreni, Natalia, Zolfino, Teresa, Rigamonti, Cristina, Vigano, Raffaella, Cuccorese, Giuseppe, Pozzoni, Pietro, Pedone, Claudio, Grasso, Simone, Picardi, Antonio, Invernizzi, Pietro, Sacco, Rodolfo, Izzi, Antonio, Fernandez-Rodriguez, Conrado, Vespasiani-Gentilucci, Umberto, and Carbone, Marco
- Published
- 2024
- Full Text
- View/download PDF
3. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
- Author
-
Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Napoli, Lucia, Conti, Fabio, Frassineti, G.L., Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Missale, Gabriele, Olivani, Andrea, Capasso, Mario, Cossiga, Valentina, Guarino, Maria, Marina Cela, Ester, Facciorusso, Antonio, Graziosi, Camilla, Lauria, Valentina, Pelecca, Giorgio, Schirripa, Marta, Chegai, Fabrizio, Raso, Armando, Bozzi, Alessio, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Plaz Torres, Maria Corina, Pieri, Giulia, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, and Trevisani, Franco
- Published
- 2023
- Full Text
- View/download PDF
4. Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib.
- Author
-
Stefanini, Bernardo, Ielasi, Luca, Casadei-Gardini, Andrea, Piscopo, Michele, Tortora, Raffaella, Lani, Lorenzo, Pressiani, Tiziana, Sansone, Vito, Sacco, Rodolfo, Magini, Giulia, Renzulli, Matteo, Foschi, Francesco Giuseppe, Piscaglia, Fabio, Tovoli, Francesco, and Granito, Alessandro
- Subjects
PROPENSITY score matching ,HEPATOCELLULAR carcinoma ,LIVER failure ,OVERALL survival ,SORAFENIB - Abstract
Background: Transarterial chemoembolisation (TACE) and radioembolisation (TARE) can lead to the deterioration of liver function, especially in cases of a high tumour burden, potentially lessening the benefits of subsequent systemic treatments. We aimed to verify whether a high number of previous transarterial treatments modified the outcomes of patients who received sorafenib as a frontline systemic treatment. Methods: A retrospective analysis of a large multicenter dataset containing prospectively collected data of sorafenib-treated patients was conducted. Results: Data from 696 patients were analysed, with 139 patients having received >two transarterial procedures before starting sorafenib. A propensity score matched 139 identified pairs of patients. Having received >two locoregional treatments was independently associated with a shorter survival (hazard ratio 1.325, 95% confidence interval 1.018–1.725, p = 0.039). This pattern was confirmed amongst responders to sorafenib, but not in progressors. A trend toward a higher rate of the permanent discontinuation of sorafenib due to liver failure (18.7 vs. 10.8%, p = 0.089) and a lower rate of eligibility for second-line treatments (24.5 vs. 17.3%, p = 0.184) was observed in patients who had received >two transarterial procedures. Conclusions: Repeated endovascular treatments negatively impacted the survival of HCC patients, especially sorafenib-responders. An early switch to systemic therapies should be considered in cases that are unlikely to respond. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.
- Author
-
De Vincentis, Antonio, primary, Ampuero, Javier, additional, Terracciani, Francesca, additional, D’Amato, Daphne, additional, Gerussi, Alessio, additional, Cristoferi, Laura, additional, Cazzagon, Nora, additional, Bonaiuto, Emanuela, additional, Floreani, Annarosa, additional, Calvaruso, Vincenza, additional, Cadamuro, Luca, additional, Degasperi, Elisabetta, additional, Morgando, Anna, additional, Vanni, Ester, additional, Lleo, Ana, additional, Colapietro, Francesca, additional, Alvaro, Domenico, additional, Castellaneta, Antonino, additional, Labanca, Sara, additional, Viganò, Mauro, additional, Distefano, Marco, additional, Palitti, Valeria Pace, additional, Ricci, Chiara, additional, De Matthaeis, Nicoletta, additional, Marzioni, Marco, additional, Gómez-Dominguez, Elena, additional, Montero, Jose-Luis, additional, Molina, Esther, additional, Garcia-Buey, Luisa, additional, Casado, Marta, additional, Berenguer, Marina, additional, Conde, Isabel, additional, Simon, Miguel-Angel, additional, Fuentes, Javier, additional, Costa-Moreira, Pedro, additional, Macedo, Guilherme, additional, Jorquera, Francisco, additional, Morillas, Rosa-Maria, additional, Presa, Jose, additional, Sousa, Jose-Manuel, additional, Gomes, Dario, additional, Santos, Luis, additional, Olveira, Antonio, additional, Hernandez-Guerra, Manuel, additional, Aburruza, Leire, additional, Santos, Arsenio, additional, Carvalho, Armando, additional, Uriz, Juan, additional, Gutierrez, Maria-Luisa, additional, Perez, Elia, additional, Chessa, Luchino, additional, Pellicelli, Adriano, additional, Marignani, Massimo, additional, Muratori, Luigi, additional, Niro, Grazia Anna, additional, Brunetto, Maurizia, additional, Ponziani, Francesca Romana, additional, Pompili, Maurizio, additional, Marra, Fabio, additional, Galli, Andrea, additional, Mussetto, Alessandro, additional, Alagna, Giuliano, additional, Simone, Loredana, additional, Bertino, Gaetano, additional, Rosina, Floriano, additional, Cozzolongo, Raffaele, additional, Russello, Maurizio, additional, Baiocchi, Leonardo, additional, Saitta, Carlo, additional, Terreni, Natalia, additional, Zolfino, Teresa, additional, Rigamonti, Cristina, additional, Vigano, Raffaella, additional, Cuccorese, Giuseppe, additional, Pozzoni, Pietro, additional, Pedone, Claudio, additional, Grasso, Simone, additional, Picardi, Antonio, additional, Invernizzi, Pietro, additional, Sacco, Rodolfo, additional, Izzi, Antonio, additional, Fernandez-Rodriguez, Conrado, additional, Vespasiani-Gentilucci, Umberto, additional, and Carbone, Marco, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Real-world experience with obeticholic acid in patients with primary biliary cholangitis
- Author
-
D’Amato, Daphne, De Vincentis, Antonio, Malinverno, Federica, Viganò, Mauro, Alvaro, Domenico, Pompili, Maurizio, Picciotto, Antonino, Palitti, Valeria Pace, Russello, Maurizio, Storato, Silvia, Pigozzi, Marie Graciella, Calvaruso, Vincenza, De Gasperi, Elisabetta, Lleo, Ana, Castellaneta, Antonino, Pellicelli, Adriano, Cazzagon, Nora, Floreani, Annarosa, Muratori, Luigi, Fagiuoli, Stefano, Niro, Grazia Anna, Feletti, Valentina, Cozzolongo, Raffaele, Terreni, Natalia, Marzioni, Marco, Pellicano, Rinaldo, Pozzoni, Pietro, Baiocchi, Leonardo, Chessa, Luchino, Rosina, Floriano, Bertino, Gaetano, Vinci, Maria, Morgando, Anna, Vanni, Ester, Scifo, Gaetano, Sacco, Rodolfo, D’Antò, Maria, Bellia, Valentina, Boldizzoni, Roberto, Casella, Silvia, Omazzi, Barbara, Poggi, Guido, Cristoferi, Laura, Gerussi, Alessio, Ronca, Vincenzo, Venere, Rosanna, Ponziani, Francesca, Cannavò, Maria, Mussetto, Alessandro, Fontana, Rosanna, Losito, Francesco, Frazzetto, Evelise, Distefano, Marco, Colapietro, Francesca, Labanca, Sara, Marconi, Giulia, Grassi, Giuseppe, Galati, Giovanni, O’Donnell, Sarah Elizabeth, Mancuso, Clara, Mulinacci, Giacomo, Palermo, Andrea, Claar, Ernesto, Izzi, Antonio, Picardi, Antonio, Invernizzi, Pietro, Carbone, Marco, and Vespasiani-Gentilucci, Umberto
- Published
- 2021
- Full Text
- View/download PDF
7. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy
- Author
-
Ielasi, Luca, primary, Stefanini, Bernardo, additional, Conti, Fabio, additional, Tonnini, Matteo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Foschi, Francesco Giuseppe, additional, Piscaglia, Fabio, additional, Granito, Alessandro, additional, and Tovoli, Francesco, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
- Author
-
Sansone, Vito, Tovoli, Francesco, Casadei-Gardini, Andrea, Di Costanzo, Giovan Giuseppe, Magini, Giulia, Sacco, Rodolfo, Pressiani, Tiziana, Trevisani, Franco, Rimini, Margherita, Tortora, Raffaella, Nardi, Elena, Ielasi, Luca, Piscaglia, Fabio, and Granito, Alessandro
- Published
- 2021
- Full Text
- View/download PDF
9. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
- Author
-
Reggidori, Nicola, primary, Bucci, Laura, additional, Santi, Valentina, additional, Stefanini, Benedetta, additional, Lani, Lorenzo, additional, Rampoldi, Davide, additional, Ghittoni, Giorgia, additional, Farinati, Fabio, additional, Masotto, Alberto, additional, Stefanini, Bernardo, additional, Mega, Andrea, additional, Biasini, Elisabetta, additional, Foschi, Francesco Giuseppe, additional, Svegliati-Baroni, Gianluca, additional, Sangiovanni, Angelo, additional, Campani, Claudia, additional, Raimondo, Giovanni, additional, Vidili, Gianpaolo, additional, Gasbarrini, Antonio, additional, Celsa, Ciro, additional, Di Marco, Mariella, additional, Giannini, Edoardo G., additional, Sacco, Rodolfo, additional, Brunetto, Maurizia Rossana, additional, Azzaroli, Francesco, additional, Magalotti, Donatella, additional, Morisco, Filomena, additional, Rapaccini, Gian Ludovico, additional, Nardone, Gerardo, additional, Vitale, Alessandro, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Tovoli, Francesco, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Cabibbo, Giuseppe, additional, Giacchetto, Carmelo Marco, additional, Giuffrida, Paolo, additional, Grassini, Maria Vittoria, additional, Grova, Mauro, additional, Rancatore, Gabriele, additional, Stornello, Caterina, additional, Adotti, Valentina, additional, Cavoli, Tancredi Li, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Napoli, Lucia, additional, Conti, Fabio, additional, Frassineti, G.L., additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Missale, Gabriele, additional, Olivani, Andrea, additional, Capasso, Mario, additional, Cossiga, Valentina, additional, Guarino, Maria, additional, Marina Cela, Ester, additional, Facciorusso, Antonio, additional, Graziosi, Camilla, additional, Lauria, Valentina, additional, Pelecca, Giorgio, additional, Schirripa, Marta, additional, Chegai, Fabrizio, additional, Raso, Armando, additional, Bozzi, Alessio, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Plaz Torres, Maria Corina, additional, Pieri, Giulia, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Cholangiocarcinoma in the Era of Immunotherapy
- Author
-
Manthopoulou, Eleni, primary, Ramai, Daryl, additional, Dhar, Jahnvi, additional, Samanta, Jayanta, additional, Ioannou, Alexandros, additional, Lusina, Ekaterina, additional, Sacco, Rodolfo, additional, and Facciorusso, Antonio, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Diversity and Uniformity in the Law
- Author
-
Sacco, Rodolfo
- Published
- 2001
- Full Text
- View/download PDF
12. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
- Author
-
Riggio, Oliviero, primary, Celsa, Ciro, additional, Calvaruso, Vincenza, additional, Merli, Manuela, additional, Caraceni, Paolo, additional, Montagnese, Sara, additional, Mora, Vincenzina, additional, Milana, Martina, additional, Saracco, Giorgio Maria, additional, Raimondo, Giovanni, additional, Benedetti, Antonio, additional, Burra, Patrizia, additional, Sacco, Rodolfo, additional, Persico, Marcello, additional, Schepis, Filippo, additional, Villa, Erica, additional, Colecchia, Antonio, additional, Fagiuoli, Stefano, additional, Pirisi, Mario, additional, Barone, Michele, additional, Azzaroli, Francesco, additional, Soardo, Giorgio, additional, Russello, Maurizio, additional, Morisco, Filomena, additional, Labanca, Sara, additional, Fracanzani, Anna Ludovica, additional, Pietrangelo, Antonello, additional, Di Maria, Gabriele, additional, Nardelli, Silvia, additional, Ridola, Lorenzo, additional, Gasbarrini, Antonio, additional, and Cammà, Calogero, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
- Author
-
Riggio, Oliviero, Celsa, Ciro, Calvaruso, Vincenza, Merli, Manuela, Caraceni, Paolo, Montagnese, Sara, Mora, Vincenzina, Milana, Martina, Saracco, Giorgio Maria, Raimondo, Giovanni, Benedetti, Antonio, Burra, Patrizia, Sacco, Rodolfo, Persico, Marcello, Schepis, Filippo, Villa, Erica, Colecchia, Antonio, Fagiuoli, Stefano, Pirisi, Mario, Barone, Michele, Azzaroli, Francesco, Soardo, Giorgio, Russello, Maurizio, Morisco, Filomena, Labanca, Sara, Fracanzani, Anna Ludovica, Pietrangelo, Antonello, Di Maria, Gabriele, Nardelli, Silvia, Ridola, Lorenzo, Gasbarrini, Antonio, Cammà, Calogero, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Riggio, Oliviero, Celsa, Ciro, Calvaruso, Vincenza, Merli, Manuela, Caraceni, Paolo, Montagnese, Sara, Mora, Vincenzina, Milana, Martina, Saracco, Giorgio Maria, Raimondo, Giovanni, Benedetti, Antonio, Burra, Patrizia, Sacco, Rodolfo, Persico, Marcello, Schepis, Filippo, Villa, Erica, Colecchia, Antonio, Fagiuoli, Stefano, Pirisi, Mario, Barone, Michele, Azzaroli, Francesco, Soardo, Giorgio, Russello, Maurizio, Morisco, Filomena, Labanca, Sara, Fracanzani, Anna Ludovica, Pietrangelo, Antonello, Di Maria, Gabriele, Nardelli, Silvia, Ridola, Lorenzo, Gasbarrini, Antonio, Cammà, Calogero, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
IntroductionHepatic encephalopathy (HE) affects the survival and quality of life of patients with cirrhosis. However, longitudinal data on the clinical course after hospitalization for HE are lacking. The aim was to estimate mortality and risk for hospital readmission of cirrhotic patients hospitalized for HE. MethodsWe prospectively enrolled 112 consecutive cirrhotic patients hospitalized for HE (HE group) at 25 Italian referral centers. A cohort of 256 patients hospitalized for decompensated cirrhosis without HE served as controls (no HE group). After hospitalization for HE, patients were followed-up for 12 months until death or liver transplant (LT). ResultsDuring follow-up, 34 patients (30.4%) died and 15 patients (13.4%) underwent LT in the HE group, while 60 patients (23.4%) died and 50 patients (19.5%) underwent LT in the no HE group. In the whole cohort, age (HR 1.03, 95% CI 1.01-1.06), HE (HR 1.67, 95% CI 1.08-2.56), ascites (HR 2.56, 95% CI 1.55-4.23), and sodium levels (HR 0.94, 95% CI 0.90-0.99) were significant risk factors for mortality. In the HE group, ascites (HR 5.07, 95% CI 1.39-18.49) and BMI (HR 0.86, 95% CI 0.75-0.98) were risk factors for mortality, and HE recurrence was the first cause of hospital readmission. ConclusionIn patients hospitalized for decompensated cirrhosis, HE is an independent risk factor for mortality and the most common cause of hospital readmission compared with other decompensation events. Patients hospitalized for HE should be evaluated as candidates for LT.
- Published
- 2023
14. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
- Author
-
Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)
- Abstract
BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.
- Published
- 2023
15. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
- Author
-
Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodino', Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De' Angelis, Gianluigi, Donnarumma, Laura, Faggiani, Roberto, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Picchio, Marcello, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Scaldaferri, Franco, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodino', Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De' Angelis, Gianluigi, Donnarumma, Laura, Faggiani, Roberto, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Picchio, Marcello, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Scaldaferri, Franco, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), and Papa, Alfredo (ORCID:0000-0002-4186-7298)
- Abstract
Background Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator. However, comparative data on the efficacy and safety of the various ADA biosimilars remains scarce. We compare the efficacy and safety of ADA biosimilars SB5, APB501, GP2017, and MSB11022 in treating IBD outpatients in a real-life Italian setting. Methods A retrospective analysis was performed on consecutive IBD outpatients with complete clinical, laboratory, and endoscopic data. Clinical activity was measured using the Mayo score in ulcerative colitis (UC) and the Harvey-Bradshaw Index in Crohn's disease (CD). The primary endpoints were the following: (1) induction of remission in patients new to biologics and patients new to ADA but previously exposed to other anti-tumor necrosis factor agents or other biologics; (2) maintenance of remission in patients switched from the ADA originator to an ADA biosimilar; and (3) safety of various biosimilars. Results A total of 533 patients were enrolled according to the inclusion criteria: 162 patients with UC and 371 patients with CD. Clinical remission was obtained in 79.6% of patients new to biologics and 59.2% of patients new to ADA but not to other biologics; clinical remission was maintained in 81.0% of patients switched from the originator, and adverse events were recorded in 6.7% of patients. There was no significant difference between the 4 ADA biosimilars for each predetermined endpoint. Conclusions Adalimumab biosimilars are effective and safe in IBD treatment, both in new patients and in patients switched from the ADA originator. No difference in efficacy and safety was found between ADA biosimilars.Lay Summary We treated 533 IBD patients with adalimumab (ADA) biosimilars SB5, APB501, GP2017, and MSB11022. No differences between these 4 ADA biosimilars were found for reaching remission in naive p
- Published
- 2023
16. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
- Author
-
Tursi, Antonio, Mocci, Giammarco, Cingolani, Linda, Savarino, Edoardo, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Napolitano, Daniele, Schiavoni, Elisa, Pugliese, Daniela, Scaldaferri, Franco, Costa, Francesco, Marzo, Manuela, Serio, Mariaelena, Scarcelli, Antonella, Bolognini, Laura, Bendia, Emanuele, Maconi, Giovanni, Cannatelli, Rosanna, Piergallini, Simona, Bodini, Giorgia, Calabrese, Francesco, Ferronato, Antonio, Pranzo, Giuseppe, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Rodinò, Stefano, Sebkova, Ladislava, Grossi, Laurino, Gaiani, Federica, dè Angelis, Gianluigi, Lorenzetti, Roberto, Allegretta, Leonardo, Cazzato, Alessia Immacolata, Scorza, Stefano, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Onidi, Francesca Maria, Usai Satta, Paolo, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Cingolani, Linda, Savarino, Edoardo, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Napolitano, Daniele, Schiavoni, Elisa, Pugliese, Daniela, Scaldaferri, Franco, Costa, Francesco, Marzo, Manuela, Serio, Mariaelena, Scarcelli, Antonella, Bolognini, Laura, Bendia, Emanuele, Maconi, Giovanni, Cannatelli, Rosanna, Piergallini, Simona, Bodini, Giorgia, Calabrese, Francesco, Ferronato, Antonio, Pranzo, Giuseppe, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Rodinò, Stefano, Sebkova, Ladislava, Grossi, Laurino, Gaiani, Federica, dè Angelis, Gianluigi, Lorenzetti, Roberto, Allegretta, Leonardo, Cazzato, Alessia Immacolata, Scorza, Stefano, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Colucci, Raffaele, Tonti, Paolo, Neve, Viviana, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Onidi, Francesca Maria, Usai Satta, Paolo, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)
- Abstract
BackgroundData regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.Research design and methodsA retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of TOF.ResultsWe enrolled 166 patients with a median follow-up of 24 (IQR 8-36) weeks. Clinical remission was achieved in 61/166 (36.7%) and 75/166 (45.2%) patients at 8-week and 24-week follow-ups, respectively. The optimization was requested in 27 (16.3%) patients. Clinical remission was achieved more frequently when TOF was used as a first/second line rather than a third/fourth line treatment (p = 0.007). Mucosal healing was reported in 46% of patients at the median follow-up time. Colectomy occurred in 8 (4.8%) patients. Adverse events occurred in 12 (5.4%) patients and severe in 3 (1.8%). One case of simple Herpes Zoster and one of renal vein thrombosis were recorded.ConclusionsOur RW data confirm that TOF is effective and safe in UC patients. It performs remarkably better when used as the first/second line of treatment.
- Published
- 2023
17. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
- Author
-
Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica
- Subjects
Liver Cancer ,Pre-TACE-Predict model ,medicine.medical_specialty ,business.industry ,Trans-arterial chemoembolization ,Pharmaceutical Science ,hepatocellular carcinoma ,medicine.disease ,Gastroenterology ,Complementary and alternative medicine ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Pharmacology (medical) ,Trans arterial chemoembolization ,business - Abstract
Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.
- Published
- 2021
18. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
- Author
-
Ielasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Stefanini, Bernardo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Garajová, Ingrid, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Understanding the Drawbacks of the Current Tumor Staging Systems: How to Improve?
- Author
-
Giacomelli, Luca, primary, Sacco, Rodolfo, additional, Papa, Simonetta, additional, and Carr, Brian I., additional
- Published
- 2023
- Full Text
- View/download PDF
20. Reply to Lissing et al. Comment on “Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947”
- Author
-
Ramai, Daryl, primary, Deliwala, Smit S., additional, Chandan, Saurabh, additional, Lester, Janice, additional, Singh, Jameel, additional, Samanta, Jayanta, additional, di Nunzio, Sara, additional, Perversi, Fabio, additional, Cappellini, Francesca, additional, Shah, Aashni, additional, Ghidini, Michele, additional, Sacco, Rodolfo, additional, Facciorusso, Antonio, additional, and Giacomelli, Luca, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis
- Author
-
Sacco, Rodolfo, primary, Ramai, Daryl, additional, Tortora, Raffaella, additional, di Costanzo, Giovan Giuseppe, additional, Burlone, Michela Emma, additional, Pirisi, Mario, additional, Federico, Piera, additional, Daniele, Bruno, additional, Silletta, Marianna, additional, Gallo, Paolo, additional, Cocuzza, Caterina, additional, Russello, Maurizio, additional, Cabibbo, Giuseppe, additional, Rancatore, Gabriele, additional, Cesario, Silvia, additional, Masi, Gianluca, additional, Marzi, Luca, additional, Mega, Andrea, additional, Granito, Alessandro, additional, Pieri, Giulia, additional, Giannini, Edoardo G., additional, Paolillo, Rosa, additional, Gadaleta-Caldarola, Gennaro, additional, Dadduzio, Vincenzo, additional, Giordano, Guido, additional, Giacomelli, Luca, additional, Papa, Simonetta, additional, Renzulli, Matteo, additional, Maida, Marcello, additional, Ghidini, Michele, additional, Borzio, Mauro, additional, and Facciorusso, Antonio, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
- Author
-
Tursi, Antonio, primary, Mocci, Giammarco, primary, Cuomo, Antonio, primary, Ferronato, Antonio, primary, Elisei, Walter, primary, Picchio, Marcello, primary, Maconi, Giovanni, primary, Scaldaferri, Franco, primary, Papa, Alfredo, primary, Italian group for switch of biologics, -, primary, Allegretta, Leonardo, primary, Aragona, Giovanni, primary, Bianco, Maria Antonia, primary, Colucci, Raffaele, primary, Della Valle, Nicola, primary, Faggiani, Roberto, primary, Forti, Giacomo, primary, Gaiani, Federica, primary, Giorgetti, GianMarco, primary, Graziani, Maria Giovanna, primary, Lofano, Katia, primary, Lorenzetti, Roberto, primary, Larussa, Tiziana, primary, Penna, Antonio, primary, Bassotti, Gabrio, primary, Cazzato, Alessia Immacolata, primary, Chiri, Stefania, primary, Clemente, Valeria, primary, Cocco, Andrea, primary, De’ Angelis, Gianluigi, primary, Donnarumma, Laura, primary, Graziosi, Camilla, primary, Le Grazie, Marco, primary, Luzza, Francesco, primary, Meucci, Costantino, primary, Monterubbianesi, Rita, primary, Pagnini, Cristiano, primary, Perazzo, Patrizia, primary, Pica, Roberta, primary, Pranzo, Giuseppe, primary, Rodino’, Stefano, primary, Sacco, Rodolfo, primary, Sebkova, Ladislava, primary, Scarcelli, Antonella, primary, Serio, Mariaelena, primary, Napolitano, Daniele, primary, Pugliese, Daniela, primary, Schiavoni, Elisa, primary, Turchini, Laura, primary, Armuzzi, Alessandro, primary, and Zampaletta, Costantino, primary
- Published
- 2022
- Full Text
- View/download PDF
23. Prognostic Role of Post-Induction Fecal Calprotectin Levels in Patients with Inflammatory Bowel Disease Treated with Biological Therapies
- Author
-
Facciorusso, Antonio, primary, Ramai, Daryl, additional, Ricciardelli, Cristina, additional, Paolillo, Rosa, additional, Maida, Marcello, additional, Chandan, Saurabh, additional, Mohan, Babu P., additional, Domislovic, Viktor, additional, and Sacco, Rodolfo, additional
- Published
- 2022
- Full Text
- View/download PDF
24. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison
- Author
-
Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, and Pellizzaro, Filippo
- Subjects
Niacinamide ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,hepatocellular carcinoma, surgery, sorafenib, bclc ,Phenylurea Compounds ,Carcinoma ,Settore MED/09 - MEDICINA INTERNA ,Liver Neoplasms ,advanced HCC ,Hepatocellular ,Antineoplastic Agents ,systemic therapies ,Sorafenib ,BCLC C ,NO ,Treatment Outcome ,macrovascular invasion ,Humans ,Hepatectomy ,Surgery ,Neoplasm Staging ,Retrospective Studies ,Liver surgery - Abstract
Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.
- Published
- 2022
25. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
- Author
-
Rognoni, Carla, Ciani, Oriana, Sommariva, Silvia, Bargellini, Irene, Bhoori, Sherrie, Cioni, Roberto, Facciorusso, Antonio, Golfieri, Rita, Gramenzi, Annagiulia, Mazzaferro, Vincenzo, Mosconi, Cristina, Ponziani, Francesca, Sacco, Rodolfo, Trevisani, Franco, and Tarricone, Rosanna
- Published
- 2018
- Full Text
- View/download PDF
26. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review
- Author
-
Ramai, Daryl, primary, Deliwala, Smit S., additional, Chandan, Saurabh, additional, Lester, Janice, additional, Singh, Jameel, additional, Samanta, Jayanta, additional, di Nunzio, Sara, additional, Perversi, Fabio, additional, Cappellini, Francesca, additional, Shah, Aashni, additional, Ghidini, Michele, additional, Sacco, Rodolfo, additional, Facciorusso, Antonio, additional, and Giacomelli, Luca, additional
- Published
- 2022
- Full Text
- View/download PDF
27. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
- Author
-
Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
BackgroundTransarterial chemoembolization (TACE) is one of the most frequently applied treatments for hepatocellular carcinoma (HCC) worldwide. In this study, we aimed at evaluating whether and how TACE application and repetition, as well as the related outcome, have changed over the last three decades in Italy. MethodsData of 7,184 patients with HCC were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. Patients were divided according to the period of diagnosis in six cohorts: P1 (1988-1993), P2 (1994-1998), P3 (1999-2004), P4 (2005-2009), P5 (2010-2014), and P6 (2015-2019). All the analyses were repeated in the overall patient population and in Barcelona Clinic Liver Cancer (BCLC) B patients, who are the subgroup of HCC patients originally supposed to receive TACE according to guidelines. TACE was defined as either the first or the main (more effective) treatment. ResultsThe proportion of patients receiving TACE as first or main therapy declined over time, and less than 50% of BCLC B patients were treated with chemoembolization from P3 onward. Conversely, TACE was widely used even outside the intermediate stage. Survival of TACE-treated patients progressively increased from P1 to P6. Although TACE was performed only once in the majority of patients, there was an increasing proportion of those receiving 2 or >= 3 treatments sessions over time. The overall survival (OS) of patients undergoing repeated treatments was significantly higher compared to those managed with a single TACE (median OS 40.0 vs. 65.0 vs. 71.8 months in 1, 2, and >= 3 TACE groups, respectively; p < 0.0001). However, after a first-line TACE, the adoption of curative therapies provided longer survival than repeating TACE (83.0 vs. 42.0 months; p < 0.0001), which in turn was associated with better outcomes compared to systemic therapies or best supportive care (BSC). ConclusionsDespite a decline in the percentage of treated patients over time, TACE has still an important rol
- Published
- 2022
28. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison
- Author
-
Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X)
- Abstract
Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.
- Published
- 2022
29. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival
- Author
-
Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G, Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pelizzaro, Filippo, Peserico, Giulia, D'Elia, Marco, Cazzagon, Nora, Russo, Francesco Paolo, Vitale, Alessandro, Giannini, Edoardo G, Piccinnu, Manuela, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
Background: An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC).Aims: We compared the 3-and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival.Methods: Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching.Results: The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9-64.0]) was not significantly different from the observed (47.0 months [35.0-58.9]; p = 0.43) and adjusted (44.9 months [33.4-56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients.Conclusions: A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics. (C) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2022
30. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
- Author
-
Giannini, Edoardo G, Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria Teresa, Sangiovanni, Angelo, Trevisani, Franco, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Giannini, Edoardo G, Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria Teresa, Sangiovanni, Angelo, Trevisani, Franco, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), and Di Marco, Maria
- Abstract
Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 vs 4.0 cm, P = 0.007). Curative treatment, feasible in 50.0% of patients, was associated with improved survival compared to palliative and supportive care (42 vs 33 vs 6 months, P<0.0001). Surveillance was associated with a non-significant improved survival (36 vs 23 months), likely due to similar rate of curative treatment in patients under (51.4%) and outside surveillance (42.6%). Conclusions: PBC patients with HCC are often elderly males with well-preserved liver function. Feasibility of curative treatment is high and associated with improved prognosis. Description of these patients may help focus surveillance to identify earlier tumours, increase their curability, and improve prognosis.
- Published
- 2022
31. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison
- Author
-
Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, and Trevisani, Franco
- Abstract
OBJECTIVE: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. BACKGROUND DATA: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. METHODS: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. RESULTS: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P [removed]0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). CONCLUSIONS: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.
- Published
- 2022
32. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
- Author
-
Tursi, Antonio, Mocci, Giammarco, Cuomo, Antonio, Ferronato, Antonio, Elisei, Walter, Picchio, Marcello, Maconi, Giovanni, Scaldaferri, Franco, Papa, Alfredo, Italian group for switch of biologics,, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Della Valle, Nicola, Faggiani, Roberto, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Pica, Roberta, Pranzo, Giuseppe, Rodino’, Stefano, Sacco, Rodolfo, Sebkova, Ladislava, Scarcelli, Antonella, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Zampaletta, Costantino, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Tursi, Antonio, Mocci, Giammarco, Cuomo, Antonio, Ferronato, Antonio, Elisei, Walter, Picchio, Marcello, Maconi, Giovanni, Scaldaferri, Franco, Papa, Alfredo, Italian group for switch of biologics,, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Della Valle, Nicola, Faggiani, Roberto, Forti, Giacomo, Gaiani, Federica, Giorgetti, Gianmarco, Graziani, Maria Giovanna, Lofano, Katia, Lorenzetti, Roberto, Larussa, Tiziana, Penna, Antonio, Bassotti, Gabrio, Cazzato, Alessia Immacolata, Chiri, Stefania, Clemente, Valeria, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Graziosi, Camilla, Le Grazie, Marco, Luzza, Francesco, Meucci, Costantino, Monterubbianesi, Rita, Pagnini, Cristiano, Perazzo, Patrizia, Pica, Roberta, Pranzo, Giuseppe, Rodino’, Stefano, Sacco, Rodolfo, Sebkova, Ladislava, Scarcelli, Antonella, Serio, Mariaelena, Napolitano, Daniele, Pugliese, Daniela, Schiavoni, Elisa, Turchini, Laura, Armuzzi, Alessandro, Zampaletta, Costantino, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)
- Abstract
Background & Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA biosimilars after replacing the ADA originator for a non-medical reason remains scarce. We aimed to compare in a real-life setting the efficacy and safety of four ADA biosimilars SB5, APB501, GP2017, and MSB11022 in IBD patients after replacing the originator for a non-medical reason.Methods: A multicenter retrospective study was performed on consecutive IBD patients, analyzing clinical, laboratory, and endoscopic data. The primary endpoints of the study were maintenance of clinical remission and safety of the different biosimilars.Results: 153 patients were enrolled, 26 with UC and 127 with CD. Clinical remission was maintained in 124 out of 153 (81%) patients after a median (IQR) follow-up of 12 (6-24) months, without any significant difference between the four ADA biosimilars. ADA biosimilars dosage was optimized in five patients (3.3%). Loss of remission was significantly higher in UC patients (10/26 patients, 38.5%) than in CD patients (19/127 patients, 14.9%, p<0.025). Adverse events occurred in 12 (7.9%) patients; the large majority were mild.Conclusions: No difference in efficacy and safety was found between ADA biosimilars when used to replace the ADA originator for a non-medical reason. However, in UC patients the replacement of ADA originator for this reason should be carefully assessed.
- Published
- 2022
33. SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
- Author
-
Trabace, Luigia, primary, Pace, Lorenzo, additional, Morgese, Maria Grazia, additional, Santo, Isabel Bianca, additional, Galante, Domenico, additional, Schiavone, Stefania, additional, Cipolletta, Dora, additional, Rosa, Anna Maria, additional, Reveglia, Pierluigi, additional, Parisi, Antonio, additional, Tucci, Paolo, additional, Pepe, Giovanni, additional, Sacco, Rodolfo, additional, Foschino Barbaro, Maria Pia, additional, Corso, Gaetano, additional, and Fasanella, Antonio, additional
- Published
- 2022
- Full Text
- View/download PDF
34. Monofocal hepatocellular carcinoma: How much does size matter?
- Author
-
Pelizzaro, Filippo, Penzo, Barbara, Peserico, Giulia, Imondi, Angela, Sartori, Anna, Vitale, Alessandro, Cillo, Umberto, Giannini, Edoardo G., Forgione, Antonella, Ludovico Rapaccini, Gian, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Giuseppe Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Sansone, Vito, Tovoli, Francesco, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Sammarco, Ambra, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Martino, Vincenzo Di, Emanuele Maria Rizzo, Giacomo, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Bonaventura, Chiara Di, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, Romagnoli, Veronica, Pelizzaro, Filippo, Penzo, Barbara, Peserico, Giulia, Imondi, Angela, Sartori, Anna, Vitale, Alessandro, Cillo, Umberto, Giannini, Edoardo G., Forgione, Antonella, Ludovico Rapaccini, Gian, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Giuseppe Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Trevisani, Franco, Farinati, Fabio, Biselli, Maurizio, Caraceni, Paolo, Garuti, Francesca, Gramenzi, Annagiulia, Neri, Andrea, Santi, Valentina, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Sansone, Vito, Tovoli, Francesco, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Sammarco, Ambra, Cela, Ester Marina, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, Moscatelli, Alessandro, Pellegatta, Gaia, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Missale, Gabriele, Inno, Alessandro, Marchetti, Fabiana, Busacca, Anita, Cammà, Calogero, Martino, Vincenzo Di, Emanuele Maria Rizzo, Giacomo, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Bevilacqua, Vittoria, Borghi, Alberto, Casadei Gardini, Andrea, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Mirici, Federica, Campani, Claudia, Bonaventura, Chiara Di, Gitto, Stefano, Coccoli, Pietro, Malerba, Antonio, Guarino, Maria, Brunetto, Maurizia, Romagnoli, Veronica, Giannini, Edoardo G, Svegliati-Baroni, Gianluca, for the Italica, Group, Pelizzaro F., Penzo B., Peserico G., Imondi A., Sartori A., Vitale A., Cillo U., Giannini E.G., Forgione A., Ludovico Rapaccini G., Di Marco M., Caturelli E., Zoli M., Sacco R., Cabibbo G., Marra F., Mega A., Morisco F., Gasbarrini A., Svegliati-Baroni G., Giuseppe Foschi F., Olivani A., Masotto A., Nardone G., Raimondo G., Azzaroli F., Vidili G., Oliveri F., Trevisani F., Farinati F., Biselli M., Caraceni P., Garuti F., Gramenzi A., Neri A., Santi V., Granito A., Muratori L., Piscaglia F., Sansone V., Tovoli F., Dajti E., Marasco G., Ravaioli F., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Sammarco A., Cela E.M., Facciorusso A., Cacciato V., Casagrande E., Moscatelli A., Pellegatta G., de Matthaeis N., Allegrini G., Lauria V., Ghittoni G., Pelecca G., Chegai F., Coratella F., Ortenzi M., Missale G., Inno A., Marchetti F., Busacca A., Qabibboz G., Camma C., Martino V.D., Emanuele Maria Rizzo G., Franze M.S., Saitta C., Sauchella A., Bevilacqua V., Borghi A., Casadei Gardini A., Conti F., Dall'Aglio A.C., Ercolani G., Mirici F., Campani C., Bonaventura C.D., Gitto S., Coccoli P., Malerba A., Guarino M., Brunetto M., Romagnoli V., Rapaccini, Gian Ludovico, and Foschi, Francesco Giuseppe
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Carcinoma, Hepatocellular ,Independent predictor ,Gastroenterology ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Hepatectomy ,Humans ,Staging system ,Neoplasm Staging ,Retrospective Studies ,Settore MED/12 - Gastroenterologia ,Hepatology ,treatment ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Liver Neoplasms ,bclc staging system ,monofocal hepatocellular carcinoma ,medicine.disease ,digestive system diseases ,Survival benefit ,Italy ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,liver resection ,prognosis ,030211 gastroenterology & hepatology ,business ,Liver cancer ,prognosi - Abstract
Background & Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5cm; SEM-HCC), 163 patients with larger tumours (>5cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0months; P 
- Published
- 2021
35. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
- Author
-
Pelizzaro, Filippo, primary, Haxhi, Selion, additional, Penzo, Barbara, additional, Vitale, Alessandro, additional, Giannini, Edoardo G., additional, Sansone, Vito, additional, Rapaccini, Gian Ludovico, additional, Di Marco, Maria, additional, Caturelli, Eugenio, additional, Magalotti, Donatella, additional, Sacco, Rodolfo, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Mega, Andrea, additional, Guarino, Maria, additional, Gasbarrini, Antonio, additional, Svegliati-Baroni, Gianluca, additional, Foschi, Francesco Giuseppe, additional, Olivani, Andrea, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, Trevisani, Franco, additional, and Farinati, Fabio, additional
- Published
- 2022
- Full Text
- View/download PDF
36. Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
- Author
-
Ielasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Sansone, Vito, additional, Marasco, Giovanni, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional
- Published
- 2021
- Full Text
- View/download PDF
37. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
- Author
-
Ramai, Daryl, primary, Facciorusso, Antonio, additional, Vigandt, Erika, additional, Schaf, Bryan, additional, Saadedeen, Waleed, additional, Chauhan, Aditya, additional, di Nunzio, Sara, additional, Shah, Aashni, additional, Giacomelli, Luca, additional, and Sacco, Rodolfo, additional
- Published
- 2021
- Full Text
- View/download PDF
38. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients
- Author
-
Cucchetti, Alessandro, D’Amico, Gennaro, Trevisani, Franco, Morelli, Maria Cristina, Vitale, Alessandro, Pinna, Antonio Daniele, Cescon, Matteo, Cillo, Umberto, Burra, Patrizia, Russo, Francesco P., Mescoli, Claudia, Rendina, Maria, Lupo, Luigi G., Losito, Francesco, Fucilli, Fabio, Brancaccio, Giusep-Pina, Persico, Marcello, Viganò, Luca, Iavarone, Massimo, D’Ambrosio, Roberta, Sangiovanni, Angelo, Renzulli, Matteo, Galati, Giovanni, Ponziani, Francesca Romana, Pompili, Maurizio, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Lai, Quirino, Melandro, Fabio, Rossi, Massimo, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Sacco, Rodolfo, Simonetti, Natalia, Morisco, Filomena, Guarino, Maria, Cabibbo, Giuseppe, Bhoori, Carlo Sposito Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, Pravisani, Riccardo, A. Cucchetti, G. D'Amico, F. Trevisani, M.C. Morelli, A. Vitale, A.D.Pinna, M. Cescon, Cucchetti, Alessandro, D’Amico, Gennaro, Trevisani, Franco, Morelli, Maria Cristina, Vitale, Alessandro, Pinna, Antonio Daniele, Cescon, Matteo, Cillo, Umberto, Burra, Patrizia, Russo, Francesco P., Mescoli, Claudia, Rendina, Maria, Lupo, Luigi G., Losito, Francesco, Fucilli, Fabio, Brancaccio, Giusep-Pina, Persico, Marcello, Viganò, Luca, Iavarone, Massimo, D’Ambrosio, Roberta, Sangiovanni, Angelo, Renzulli, Matteo, Galati, Giovanni, Ponziani, Francesca Romana, Pompili, Maurizio, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Lai, Quirino, Melandro, Fabio, Rossi, Massimo, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Sacco, Rodolfo, Simonetti, Natalia, Morisco, Filomena, Guarino, Maria, Cabibbo, Giuseppe, Bhoori, Carlo Sposito Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, and Pravisani, Riccardo
- Subjects
Male ,Time Factors ,Sustained Virologic Response ,Hepatocellular carcinoma ,Hepacivirus ,Direct-acting antiviral ,Direct-acting antivirals ,medicine.disease_cause ,Gastroenterology ,Competing risk ,Hepatitis C ,Markov model ,Survival benefit ,Sustained virological response ,Hepatology ,0302 clinical medicine ,Risk Factors ,030212 general & internal medicine ,biology ,Incidence ,Incidence (epidemiology) ,Liver Neoplasms ,Middle Aged ,Markov Chains ,Competing risk Direct-acting antivirals Hepatitis C Hepatocellular carcinoma Markov model Survival benefit Sustained virological response ,Italy ,Liver Neoplasm ,Female ,030211 gastroenterology & hepatology ,Human ,Adult ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factor ,Hepatitis C virus ,Antiviral Agents ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Antiviral Agent ,Hepaciviru ,business.industry ,Risk Factor ,Carcinoma ,Hepatocellular ,Markov Chain ,medicine.disease ,biology.organism_classification ,digestive system diseases ,Settore MED/18 - Chirurgia Generale ,Liver function ,Varices ,business - Abstract
Background: The achievement of high rates of sustained virological response (SVR) with direct-acting antivirals (DAAs) in hepatitis C virus (HCV) infected patients will reduce decompensating terminal events. Aims: To investigate whether hepatocellular carcinoma (HCC) occurrence could change due to the DAA-induced increase in life-expectancy. Methods: A Markov model was built on clinical data of 494 cirrhotic patients and available literature to estimate probabilities of “death before HCC” and of “HCC occurrence” without and with DAA. Results: In comparison to untreated patients, DAA therapy reduced the 20-year mortality before HCC by 21.9% in patients without varices and by 21.5% in those with varices, considering an SVR of 95% and no direct effect on hepatocarcinogenesis. Tumour occurrence increased by 5%–8.2% and the proportion of HCCs diagnosed in compensated stages increased to >98%. If we consider DAA as having “anti-tumoral” effects, the benefit becomes greater, achieving a 20-year survival of 81.5% in patients without varices, and 52.2% in patients with varices. Instead, if we consider DAA as having a “pro-tumoral” effect, then, the increased incidence of HCC nullifies the survival benefits. Conclusion: DAAs drastically reduce the mortality caused by the liver function worsening, increasing the proportion of HCCs diagnosed in compensated stages. Knowledge of the DAA effect on hepatocarcinogenesis remains pivotal. © 2017 Editrice Gastroenterologica Italiana S.r.l.
- Published
- 2018
39. Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab
- Author
-
Tursi, Antonio, primary, Mocci, Giammarco, primary, Elisei, Walter, primary, Allegretta, Leonardo, primary, Colucci, Raffaele, primary, Della Valle, Nicola, primary, De Medici, Antonio, primary, Faggiani, Roberto, primary, Ferronato, Antonio, primary, Forti, Giacomo, primary, Larussa, Tiziana, primary, Lorenzetti, Roberto, primary, Luzza, Francesco, primary, Penna, Antonio, primary, Pranzo, Giuseppe, primary, Rodinò, Stefano, primary, Sacco, Rodolfo, primary, Sebkova, Ladislava, primary, Zampaletta, Costantino, primary, Graziosi, Camilla, primary, Picchio, Marcello, primary, Bergna, Irene Maria Bambina, primary, and Maconi, Giovanni, primary
- Published
- 2021
- Full Text
- View/download PDF
40. Hospital Frailty Risk Score Is Independently Associated with Mortality and Encephalopathy in Hospitalized Patients with Hepatocellular Carcinoma
- Author
-
Ramai, Daryl, primary, Dang-Ho, Khoi P., additional, Kewalramani, Anjali, additional, Bandaru, Praneeth, additional, Sacco, Rodolfo, additional, Giacomelli, Luca, additional, Shah, Aashni, additional, Papa, Simonetta, additional, Cappellini, Francesca, additional, Perversi, Fabio, additional, di Nunzio, Sara, additional, and Facciorusso, Antonio, additional
- Published
- 2021
- Full Text
- View/download PDF
41. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
- Author
-
Granito, Alessandro, primary, Facciorusso, Antonio, additional, Sacco, Rodolfo, additional, Bartalena, Laura, additional, Mosconi, Cristina, additional, Cea, Ugo Vittorio, additional, Cappelli, Alberta, additional, Antonino, Matteo, additional, Modestino, Francesco, additional, Brandi, Nicolò, additional, Tovoli, Francesco, additional, Piscaglia, Fabio, additional, Golfieri, Rita, additional, and Renzulli, Matteo, additional
- Published
- 2021
- Full Text
- View/download PDF
42. Utility-Based Criteria for Selecting Patients With Hepatocellular Carcinoma for Liver Transplantation: A Multicenter Cohort Study Using the Alpha-Fetoprotein Model as a Survival Predictor
- Author
-
Vitale, Alessandro, Farinati, Fabio, Burra, Patrizia, Trevisani, Franco, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Svegliati Baroni, Gianluca, Virdone, Roberto, Chiaramonte, Maria, Spolverato, Gaya, and Cillo, Umberto
- Published
- 2015
- Full Text
- View/download PDF
43. Organizing a Scholarly Congress.
- Author
-
Sacco, Rodolfo
- Abstract
In a tongue-in-cheek fashion, practical and creative suggestions for planning and carrying out a conference on legal scholarship are discussed, including topic selection, financing, choice of speakers, working sessions, logistical planning, and publication of the proceedings. (MSE)
- Published
- 1990
44. Mute Law
- Author
-
Sacco, Rodolfo
- Published
- 1995
- Full Text
- View/download PDF
45. Legal Formants: A Dynamic Approach to Comparative Law (Installment I of II)
- Author
-
Sacco, Rodolfo
- Published
- 1991
- Full Text
- View/download PDF
46. Effectiveness of hemostatic powders in lower gastrointestinal bleeding: a systematic review and meta-analysis
- Author
-
Facciorusso, Antonio, additional, Bertini, Marco, additional, Bertoni, Michele, additional, Tartaglia, Nicola, additional, Pacilli, Mario, additional, Ramai, Daryl, additional, Mohan, Babu P., additional, Chandan, Saurabh, additional, Ambrosi, Antonio, additional, and Sacco, Rodolfo, additional
- Published
- 2021
- Full Text
- View/download PDF
47. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
- Author
-
Renzulli, Matteo, primary, Ramai, Daryl, additional, Singh, Jameel, additional, Sinha, Samridhi, additional, Brandi, Nicolò, additional, Ierardi, Anna Maria, additional, Albertini, Elisa, additional, Sacco, Rodolfo, additional, Facciorusso, Antonio, additional, and Golfieri, Rita, additional
- Published
- 2021
- Full Text
- View/download PDF
48. Transarterial chemoembolization as adjuvant treatment after surgery: The cure of huge hepatocellular carcinoma?
- Author
-
Chierici, Andrea, primary, Ofosu, Andrew, additional, Cincione, Ivan, additional, Sacco, Rodolfo, additional, Cotsoglou, Christian, additional, and Facciorusso, Antonio, additional
- Published
- 2021
- Full Text
- View/download PDF
49. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients
- Author
-
Pelizzaro, Filippo, Vitale, Alessandro, Sartori, Anna, Vieno, Andrea, Penzo, Barbara, Russo, Francesco, Frigo, Anna, Giannini, Edoardo, Piccinnu, Manuela, Rapaccini, Gian, Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Celsa, Ciro, Marra, Fabio, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Coccoli, Pietro, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia, Trevisani, Franco, Farinati, Fabio, Group, on behalf of ITA.LI.CA study, Pelizzaro F., Vitale A., Sartori A., Vieno A., Penzo B., Russo F.P., Frigo A.C., Giannini E.G., Piccinnu M., Rapaccini G.L., Di Marco M., Caturelli E., Zoli M., Sacco R., Celsa C., Marra F., Mega A., Guarino M., Gasbarrini A., Svegliati-Baroni G., Foschi F.G., Olivani A., Masotto A., Coccoli P., Raimondo G., Azzaroli F., Vidili G., Brunetto M.R., Trevisani F., and Farinati F.
- Subjects
Cancer Research ,medicine.medical_specialty ,Hepatocellular carcinoma ,Settore MED/12 - GASTROENTEROLOGIA ,Cancer stage ,Independent predictor ,Logistic regression ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,Long-term survival ,0302 clinical medicine ,Internal medicine ,Long term survival ,medicine ,Treatment ,Surveillance ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Confounding ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Oncology ,030220 oncology & carcinogenesis ,Baseline characteristics ,030211 gastroenterology & hepatology ,business - Abstract
Purpose: We aimed at assessing the impact of surveillance on long-term survival in HCC patients. Methods: From the ITA.LI.CA database, we selected 1028 cases with long (≥5 years, LS group) and 2721 controls with short-term survival (<, 5 years, SS group). The association between surveillance and LS was adjusted for confounders by multivariable logistic regression analysis. Survival of surveilled patients was presented both as observed and corrected for the lead-time bias, and the comparison of survival between surveillance and no surveillance groups was also performed after balancing the baseline characteristics with inverse probability weights (IPW). Results: LS patients were more frequently diagnosed under surveillance (p <, 0.0001), and had more favorable baseline characteristics. Surveillance was an independent predictor of LS (OR = 1.413, 95% CI 1.195–1.671, p <, 0.0001). The observed and the lead-time corrected survival of surveilled patients were significantly longer compared to the survival of not surveilled patients (p <, 0.0001 and p = 0.0008, respectively). In IPW adjusted populations, no survival differences were demonstrated between the two groups (p = 0.30). Conclusions: Surveillance, increasing early-stage diagnosis and applicability of curative treatments, is a fundamental determinant of long-term survival in HCC patients. A wide implementation of surveillance programs should be pursued in order to improve HCC patients’ prognosis.
- Published
- 2021
50. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database
- Author
-
Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Miele, Luca (ORCID:0000-0003-3464-0068), Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Miele, Luca (ORCID:0000-0003-3464-0068)
- Abstract
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort. Methods We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC. Results MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006). Conclusions The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
- Published
- 2021
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.